CPHI
China Pharma Holdings, Inc.
There isn't enough reported data to score CPHI yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CPHI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Stable | |
| Weak |
CPHI's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CPHI PE Valuation
CPHI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CPHI Forward outlook
There aren't enough analyst estimates for CPHI to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CPHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.42 | +$1.08 |
| Q1 2026 | -$0.54 | +$1.70 |
| Q4 2025 | -$0.74 | +$1.96 |
| Q3 2022 | -$35.00 | +$10.00 |
| Q2 2022 | -$35.00 | +$10.00 |
| Q1 2022 | -$35.00 | $0.00 |
| Q4 2021 | -$35.00 | $0.00 |
| Q3 2021 | -$45.00 | +$190.00 |
CPHI lost $0.42 per share over the past year, a smaller loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CPHI on earnings quality, reporting a profit while its opponent remains loss making.
CPHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $948.3K | -7.5% |
| Q1 2026 | $983.5K | -13% |
| Q4 2025 | $1.2M | +8.1% |
| Q3 2025 | $756.2K | -31% |
| Q2 2025 | $1M | +11% |
| Q1 2025 | $1.1M | -17% |
| Q4 2024 | $1.1M | -47% |
| Q3 2024 | $1.1M | -39% |
CPHI's revenue has slid since its 2020 peak: $948,340 last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -151% | -87 points |
| Q1 2026 | -114% | -47 points |
| Q4 2025 | -98% | +7.6 points |
| Q3 2025 | -83% | +16 points |
| Q2 2025 | -64% | +87 points |
| Q1 2025 | -67% | +0.1 points |
| Q4 2024 | -105% | -50 points |
| Q3 2024 | -99% | -59 points |
CPHI's operating margin was −151% last quarter, down 87 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CPHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CPHI on profitability, with a higher operating margin.
CPHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2025 | -$237.6K | -$190.6K |
| Q2 2025 | $291.1K | +$363.9K |
| Q1 2025 | -$116.1K | +$469K |
| Q3 2024 | -$47K | -105% |
| Q2 2024 | -$72.7K | +$143.7K |
| Q1 2024 | -$585.2K | +$883.1K |
| Q4 2023 | -$22.3K | -104% |
| Q3 2023 | $1M | +$1M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with CPHI at up 110%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CPHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +58% | +14.9M shares |
| 1 year | +1142% | +37.3M shares |
| 3 years | +40409% | +40.4M shares |
| 5 years | +46392% | +40.4M shares |
| Available history | +46392% | +40.4M shares |
CPHI has 41M diluted shares, up 1142% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CPHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CPHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 1,068.6x | High |
| Q1 2022 | 217.7x | High |
| Q4 2021 | 20.8x | High |
| Q1 2021 | 92.7x | High |
| Q4 2020 | 42.3x | High |
CPHI's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CPHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 5.4 | Oversold |
CPHI's weekly RSI is 41 (neutral) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CPHI PE vs Healthcare Sector
CPHI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CPHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 18% below |
| 20 week MA | $0.84 | 33% below |
| 50 week MA | $0.86 | 35% below |
| 100 week MA | $1.37 | 59% below |
| 200 week MA | $5.78 | 90% below |
CPHI is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CPHI on trend strength, trading above more of its moving averages.
CPHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $121.5 | $223.8 | +84% |
| 2021 | $223.8 | $215.1 | -3.9% |
| 2022 | $215.1 | $58.3 | -73% |
| 2023 | $58.3 | $6.05 | -90% |
| 2024 | $6.05 | $2.10 | -65% |
| 2025 | $2.10 | $1.29 | -39% |
| 2026 YTD | $1.29 | $0.56 | -57% |
CPHI has finished five years in a row lower, and it's down 57% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CPHI on returns for 2026, with the stronger performance.